Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus
- Status
- UnknownResults none
- Why it is watched
- population of special interest (non-obese / healthy / non-diabetic)
- Who it enrolls
- age 18 Years to 35 Years; healthy volunteers accepted; no BMI minimum stated; conditions: Type 1 Diabetes
- Interventions
- Semaglutide weekly injection
- Conditions
- Type 1 Diabetes
- Phase and size
- Phase 1, Phase 2 · 120 participants
- Dates
- Start 2024-01-01
Primary completion 2024-12-31 - Sponsor
- Ministry of Health, Saudi Arabia (Other gov)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- change in HA1c and mounts of insulin of basal and bolus which will be taken daily is the same or decreased after one year of follow upTime Frame: one year
02Eligibility
Who can take part
Inclusion Criteria: early diagnosed type 1 diabetic patients were diagnosed in the last 6 months age of two groups: from 18-35 years basal-bolus insulin patients Exclusion Criteria: no oral hypoglycemic drugs no pregnancy no hypoglycemic drugs or immunosuppressant no history of diabetic ketoacidosis
03Change log
Registry changes
No changes recorded since the trial was added.